INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Innovaderm Launches a New Web Page Dedicated to its Customized Stand-Alone Biometrics Solutions!

Indero

Indero

Team of Experts

Author picture

Innovaderm’s specialized Biometrics Boutique is a testament to our commitment to redefining excellence in biostatistics and data management.

We tailor our comprehensive back-end solutions to meet the unique needs of our clients with only 1 goal in mind: Delivering exceptional results and quality data.

Visit our new biometrics page!

Our team of 45+ skilled biometrics professionals has over 200 studies, in dozens of indications from different therapeutic areas, involving biostatistics and/or data management under their belt including:

  • Rheumatology;
  • Ophtalmology;
  • Neurology;
  • Cardiovascular diseases;
  • Respiratory diseases;
  • And more

 

Our dedication to reliability and precision was proven, even outside of the dermatology field. Read what Theratechnologies has to say on the subject.

Experience our biometrics excellence, visit our brand-new dedicated webpage.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >